Crown Bioscience

Crown Bioscience A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit. Find out more: www.crownbio.com

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical, and translational platforms to advance oncology and immuno-oncology. Known for their

high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has 12 facilities in the US, Europe, and APAC.

Antibody-Drug Conjugates (ADCs) combine targeted antibodies with potent toxins – making it essential to understand their...
06/05/2026

Antibody-Drug Conjugates (ADCs) combine targeted antibodies with potent toxins – making it essential to understand their stability and how they break down in the body.

Our AACR 2026 Poster shows how tracking the Drug-to-Antibody Ratio (DAR) with a robust ADC testing platform provides data that’s critical for de-risking drug development.

Discover how specific linker types and payloads influence DAR across different species: https://hubs.la/Q04kfV-v0

Successful oncology drug discovery rests on high quality data.With flexible licensing options for datasets spanning WES,...
06/04/2026

Successful oncology drug discovery rests on high quality data.

With flexible licensing options for datasets spanning WES, RNA-Seq, proteomics and more, accessing OMICS and SoC datasets has never been easier.

Discover data licensing opportunities from our industry-leading PDX and organoid models: https://hubs.la/Q04k17YT0

We’re pleased to launch our Small Panel Bone Marrow Niche platform.Developed as a streamlined entry point to our 3D BMN ...
06/03/2026

We’re pleased to launch our Small Panel Bone Marrow Niche platform.

Developed as a streamlined entry point to our 3D BMN platform, the Small Panel format reduces study conditions from 30+ to fewer than 15, helping researchers access a more flexible and resource-efficient approach for hematological cancer studies.

The platform enables teams to:
• Model a more physiologically relevant 3D bone marrow microenvironment
• Evaluate drug response in AML, MM and other hematological malignancies
• Generate high-content imaging data to support translational insights
• Explore promising study ideas with reduced upfront commitment

Read the fact sheet: https://hubs.la/Q04jT6ZM0

Biomarker data is only powerful if the results are reproducible, actionable, and clinically meaningful.Our unified appro...
06/02/2026

Biomarker data is only powerful if the results are reproducible, actionable, and clinically meaningful.

Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy.

Unlock insights from your most complex datasets: https://hubs.la/Q04jtMz50

Clinical biomarker strategies are essential for guiding drug development, but their complexity can delay insights and li...
06/01/2026

Clinical biomarker strategies are essential for guiding drug development, but their complexity can delay insights and limit impact.

From assay development to data analysis, our integrated clinical biomarker services simplify the whole process, allowing us to:

• Align biomarker strategies with clinical endpoints
• Generate consistent, high-quality data across studies
• Support meaningful interpretation with advanced analytics

Discover how our integrated biomarker services support more informed clinical decisions: https://hubs.la/Q04jx2kF0

Intrapatient organoid models can provide a more accurate recapitulation of corresponding parental tumors, supporting mor...
05/29/2026

Intrapatient organoid models can provide a more accurate recapitulation of corresponding parental tumors, supporting more translationally relevant in vitro research.

This month, we’re highlighting PA20006B, a primary-site pancreatic organoid model derived from a patient sample.

Use models like PA20006B to help recapitulate key characteristics of parental tumors and support more informed evaluation of tumor biology and therapeutic response.

Explore PA20006B and other available models in the Crown Bioscience databases: https://hubs.la/Q04jrBC00

Looking for the best customer experience available in the industry? Explore our monthly Customer Satisfaction Report: ht...
05/27/2026

Looking for the best customer experience available in the industry? Explore our monthly Customer Satisfaction Report: https://hubs.la/Q04h_TpR0

How do we enable deeper insights into CAR-T efficacy within complex tumor microenvironments? Our AACR 2026 Poster demons...
05/26/2026

How do we enable deeper insights into CAR-T efficacy within complex tumor microenvironments? Our AACR 2026 Poster demonstrates how organoid fibroblast co-culture systems, combined with high-content imaging (HCI), improve the assessment of tumor killing, immune infiltration and resistance mechanisms.

See how this approach bridges the gap between mechanistic insights and translational relevance in immuno-oncology: https://hubs.la/Q04hSF-p0

Crown Bioscience will be attending the 74th ASMS Conference on Mass Spectrometry and Allied Topics in San Diego.We look ...
05/22/2026

Crown Bioscience will be attending the 74th ASMS Conference on Mass Spectrometry and Allied Topics in San Diego.

We look forward to connecting with industry colleagues to discuss the latest advances supporting bioanalysis, translational research and drug development.

If you’re attending, schedule a meeting with Chengfei Ruan to learn more about how Crown Bioscience can support your research programs.

Schedule a meeting: https://hubs.la/Q04htc3X0

05/21/2026

How do you accurately predict clinical outcomes? By bridging the gap between drug concentration and biological effect.

In this on-demand webinar, Rekha Pal, PhD, provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success.

From mechanistic modeling to risk mitigation, see how early PK/PD integration can accelerate your transition from bench to clinic.

Watch now: https://hubs.la/Q04hsdTt0

Address

16550 West Bernardo Drive
San Diego, CA
92127

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+18586222900

Website

Alerts

Be the first to know and let us send you an email when Crown Bioscience posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category